Silence Therapeutics (SLN) Liabilities and Shareholders Equity: 2023-2025
Historic Liabilities and Shareholders Equity for Silence Therapeutics (SLN) over the last 3 years, with Sep 2025 value amounting to $146.8 million.
- Silence Therapeutics' Liabilities and Shareholders Equity was N/A to $146.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $700.0 million, marking a year-over-year change of. This contributed to the annual value of $202.6 million for FY2024, which is 69.64% up from last year.
- As of Q3 2025, Silence Therapeutics' Liabilities and Shareholders Equity stood at $146.8 million, which was down 11.16% from $165.2 million recorded in Q2 2025.
- In the past 5 years, Silence Therapeutics' Liabilities and Shareholders Equity registered a high of $202.6 million during Q4 2024, and its lowest value of $119.4 million during Q4 2023.
- Moreover, its 3-year median value for Liabilities and Shareholders Equity was $165.2 million (2025), whereas its average is $163.9 million.
- Examining YoY changes over the last 5 years, Silence Therapeutics' Liabilities and Shareholders Equity showed a top increase of 69.64% in 2024 and a maximum decrease of 69.64% in 2024.
- MRQ analysis of 3 years shows Silence Therapeutics' Liabilities and Shareholders Equity stood at $119.4 million in 2023, then skyrocketed by 69.64% to $202.6 million in 2024, then decreased by 27.56% to $146.8 million in 2025.
- Its Liabilities and Shareholders Equity stands at $146.8 million for Q3 2025, versus $165.2 million for Q2 2025 and $185.3 million for Q1 2025.